Merlintrader’s Daily Briefing

Monday, July 27, 2026 — the weekend removed the single variable that had been driving every other price. Washington paused its strikes on Iran after two weeks of near-daily attacks and Tehran signalled it will hold fire for as long as that lasts, sending Brent down 5.77% to $91.20 and lifting Nasdaq 100 futures 1.16%. Gold rose rather than fell, because cheaper crude lowers the inflation risk that had pushed the odds of a Federal Reserve rate increase from roughly 11% to 38% in ten days. Into that, Sunday delivered the largest financing headline of the artificial-intelligence cycle: Nvidia in talks to guarantee about $250 billion for an OpenAI data centre in Ohio that will cost more than $500 billion in total. The Fed decides on Wednesday, Microsoft and Meta report the same afternoon, Apple and Amazon follow on Thursday with the advance second-quarter GDP reading, and the June inflation deflator closes the week.

The pause that reset the tape
  • The decision — The president paused strikes on Iran over the weekend after two weeks of near-daily attacks, and Tehran signalled it will hold its own fire for as long as Washington refrains. Neither side has called it a ceasefire, and nothing has been signed.Geopolitics
  • Crude — Brent fell $5.58, or 5.77%, to $91.20, having traded as much as 7.4% lower and below $90 at one point. West Texas Intermediate lost $4.91, or 5.50%, to $84.40.Energy
  • Futures — Dow futures were up 305 points, or 0.59%, S&P 500 futures gained 0.72% and Nasdaq 100 futures advanced 1.16%, with the largest relief concentrated in the index that had lost the most last week.Indices
  • Gold — Bullion rose $31.20, or 0.77%, to $4,102.00 — up rather than down on the de-escalation, because a lower oil price lowers the inflation risk that had been pushing rate expectations higher.Metals
  • Dollar and Asia — The dollar index slipped 0.25% to 101.23, shares and bonds bounced across Asia and Japanese government bond futures rose as the crude move fed through to inflation expectations.Markets
What the pause does not fix
  • The mechanism — The barrels never left the market. What moved was the probability attached to their leaving, which is why a headline could take more than 5% out of crude without a single change in supply. That premium can rebuild as quickly as it came out.Energy
  • Still unresolved — The ceasefire agreed earlier in the month remains broken, no formal diplomatic track has been confirmed by either government, and NBC reported that U.S. defences have been letting some Iranian projectiles through rather than intercepting everything.Geopolitics
  • The Caspian file — Ukraine said on Saturday its long-range strikes hit Iran-linked cargo vessels and a warship in the Caspian Sea. Iran said one crew member was killed. A third party striking Iranian shipping is a source of escalation that neither Washington nor Tehran controls.Geopolitics
Nvidia writes the cheque of the cycle
  • The report — The Wall Street Journal reported on Sunday that Nvidia is in talks to guarantee roughly $250 billion of financing for OpenAI, covering the lease and debt on a 10-gigawatt data centre that SoftBank’s energy arm is developing in southern Ohio.AI
  • The full size — The project is expected to cost more than $500 billion once the chips inside it are counted. The $250 billion guarantee excludes those chips; Nvidia is separately discussing financing OpenAI’s chip purchases worth up to $350 billion.AI
  • What each side gets — For OpenAI it is the first step toward owning its infrastructure rather than renting it from Microsoft, Amazon and Oracle. For Nvidia it locks in demand for its own chips for years. Talks are early and could collapse or be restructured.AI
  • Why it lands now — It arrives in the same week the market has been marking down companies for spending on artificial intelligence. A vendor guaranteeing a customer’s financing to buy the vendor’s product is the most direct answer yet to the question of who carries the risk of the buildout.AI
Memory: China plants a flag
  • CXMT — ChangXin Memory Technologies debuts in Shanghai after Asia’s largest initial public offering, and has become mainland China’s most valuable listed company. The listing lands days after a Korea-led selloff knocked the U.S. memory complex.Chips
  • Nvidia and Naver — Nvidia is acquiring $1 billion of newly issued shares in South Korea’s Naver, extending the pattern of the chipmaker taking equity positions across its own customer base.Chips
  • The context — Memory pricing has been one of the stronger fundamental stories of this cycle. A domestic Chinese champion at that scale changes the long-run supply picture rather than the current quarter.Chips
Corporate: the deal tape reopens
  • United and Delta — United reportedly approached Delta Air Lines about a potential merger. A combination of two of the three largest U.S. carriers would face an antitrust review with no recent precedent, and the report lands as lower crude removes the fuel-cost pressure both had been carrying.M&A
  • Paramount and Warner — Paramount has paused its $111 billion agreement for Warner Bros. by several months, delaying rather than abandoning the largest media transaction on the board.M&A
  • Perpetual — Sweden’s EQT returned with a revised $1.78 billion takeover offer for Australia’s Perpetual.M&A
  • Brown-Forman — The board said Sazerac’s unsolicited proposal is not actionable, closing the door on an approach for the spirits group without engaging.M&A
  • Shein — The retailer swung to a loss as the new U.S. trade rules cut into sales, an early read on how the tariff regime is landing on cross-border e-commerce.Retail
Trade: three files still open
  • Beijing — China’s commerce ministry added 14 European entities to its export control list on Friday, barring exports of Chinese dual-use goods including some rare earths. Rheinmetall, Vigo Photonics, Tatra and Cavok UAS are among them, answering the European Union’s twenty-first Russia sanctions package.Trade
  • Brussels — A Section 301 investigation into European Union trade practices has been announced over the bloc’s fines on American technology companies, following a 2.95 billion euro antitrust penalty on Google’s ad tech business.Trade
  • Pharmaceuticals — The generic drug plan starts its two-year transition on Saturday at a zero rate under Section 232, stepping to 100% and then 200%. Most generics sold in the United States are made in Europe and India.Health Policy
Biotech: three decisions in four days
  • Wednesday — The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee reviews Capricor’s deramiocel in Duchenne muscular dystrophy from 10:00 a.m. to 4:30 p.m. Eastern. The PDUFA target action date is 22 August and the filing has prior complete response history.Biotech
  • Thursday — Replimune faces a panel on RP1 with nivolumab in advanced melanoma after anti-PD-1 therapy, with a goal date of 2 August — an unusually short gap between hearing and decision.Biotech
  • Thursday — Viatris has the target action date for its 505(b)(2) application covering a low-dose estrogen combined hormonal contraceptive weekly patch, supported by the Phase 3 Luminous study.Biotech
The Fed and the week
  • Today — June durable goods orders open the week, the first read on business capital spending outside the technology complex.Macro
  • Tuesday — The S&P Case-Shiller home price index and Conference Board consumer confidence arrive as the two-day Federal Open Market Committee meeting begins.Macro
  • Wednesday — The rate decision lands at 2:00 p.m. Eastern with Chair Kevin Warsh’s press conference half an hour later, and Microsoft, Meta, Arm and Qualcomm report the same day.Rates
  • The rate debate — Futures had moved to price roughly a 38% chance of a quarter-point increase, up from about 11% on 15 July, almost entirely on the oil move. That premium is what unwound over the weekend, which cuts against the hawkish case the market had been building.Rates
  • Thursday — The advance reading of second-quarter GDP arrives with weekly jobless claims, the Bank of England decides, and Apple and Amazon report after the close.Macro
  • Friday — The June personal consumption expenditures price index and the second-quarter employment cost index close the week, alongside the Bank of Japan, euro-area inflation and results from Exxon Mobil and Chevron.Macro
  • Earnings backdrop — With more than 80 S&P 500 members reported, second-quarter earnings growth is tracking near 26.5% against a year earlier. Beats have not been the problem; capital spending guidance has.Earnings
Read the full Daily Briefing

Biotech Catalyst Calendar 2026

Last updated: 22 July 2026

Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.

Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: July 15 → September 30, 2026. Compact homepage board for FDA decisions, advisory committees, regulatory submissions and major clinical readouts. October and later events are excluded from this widget.

38Active
20FDA / Reg
18Data / Filing
Jul 27Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$NRXPKETAFREEJul 29GDUFA Preservative-free IV ketamine

NRx Pharmaceuticals. FDA-assigned GDUFA goal date for the KETAFREE ANDA, a preservative-free intravenous ketamine formulation. This is a generic-drug decision, not a PDUFA for NRX-100 or NRX-101; the KETAFREE proprietary name remains subject to FDA review.

$CAPRderamiocel panelJul 29AdCom Panel before Aug PDUFA

Capricor. FDA advisory committee for deramiocel in Duchenne muscular dystrophy cardiomyopathy. Panel tone and briefing documents are the key pre-PDUFA read-through.

$VTRSMR-100A-01Jul 30PDUFA Low-dose estrogen weekly contraceptive patch

Viatris. FDA target action date for the 505(b)(2) NDA for the investigational low-dose estrogen combined hormonal contraceptive weekly patch. Supported by the Phase 3 Luminous study, NCT05139121.

$REPLRP1 panelJul 30AdCom Melanoma panel review

Replimune. FDA advisory committee for RP1 plus nivolumab in advanced melanoma after anti-PD-1 therapy. Single-arm evidence risk remains central.

$REPLRP1Aug 2PDUFA Melanoma BLA resubmission

Replimune. BLA resubmission goal date for RP1. This is a very compressed AdCom-to-PDUFA setup with elevated regulatory risk.

$MRNAmFLUSIVAAug 5PDUFA mRNA seasonal flu

Moderna. BLA PDUFA for mRNA seasonal flu vaccine candidate in adults 50+. More platform and lifecycle read-through than pure small-cap binary.

$REGNgaretosmabAugFDA FOP ultra-rare disease

Regeneron. BLA target action month for garetosmab in adult fibrodysplasia ossificans progressiva. Month-only calendar item.

$LNTHMK-6240Aug 13NDA Tau PET imaging

Lantheus. NDA PDUFA for MK-6240 tau PET imaging in Alzheimer’s disease. Diagnostic/imaging catalyst, not a therapeutic efficacy binary.

$CAPRderamiocelAug 22PDUFA DMD cardiomyopathy

Capricor. BLA PDUFA for deramiocel in Duchenne muscular dystrophy cardiomyopathy. Prior CRL history and July AdCom make this highly binary.

$RAREDTX401Aug 23BLA GSDIa gene therapy

Ultragenyx. Priority Review BLA PDUFA for DTX401 in glycogen storage disease type Ia. First of two near-term Ultragenyx gene-therapy decisions.

$BIIBLeqembi IQLIKAug 24sBLA SC starting dose

Biogen / Eisai. sBLA PDUFA for once-weekly subcutaneous Leqembi starting-dose use. Large-cap Alzheimer’s lifecycle catalyst.

$JAZZZiihera comboAug 25sBLA 1L HER2+ GEA

Jazz Pharmaceuticals. sBLA PDUFA for Ziihera combination use in first-line HER2-positive gastroesophageal adenocarcinoma.

$GILDBIC/LENAug 27NDA Once-daily HIV regimen

Gilead. NDA PDUFA for bictegravir/lenacapavir in virologically suppressed adults. Strategic HIV franchise catalyst.

$PTGXrusfertideQ3PDUFA Polycythemia vera

Protagonist / Takeda. Priority Review NDA window for rusfertide in polycythemia vera. Exact date not pinned in this compact board.

$NUVLzidesamtinibSep 18NDA ROS1+ NSCLC

Nuvalent. NDA PDUFA for zidesamtinib in ROS1-positive non-small-cell lung cancer. Important targeted-oncology regulatory event.

$RAREUX111Sep 19Risk Sanfilippo A gene therapy

Ultragenyx. Resubmitted BLA PDUFA for UX111 in Sanfilippo syndrome type A. CMC and facility risk remain the key swing factors.

$IONSzilganersenSep 22NDA Alexander disease

Ionis. NDA PDUFA for zilganersen in Alexander disease. Rare neurological disease Priority Review event.

$BFRIAmeluz PDTSep 28sNDA Superficial BCC expansion

Biofrontera. PDUFA for Ameluz photodynamic therapy sNDA seeking expansion into superficial basal cell carcinoma. Small-cap liquidity can amplify reaction.

$SRRKapitegromabSep 30BLA Spinal muscular atrophy

Scholar Rock. BLA PDUFA for apitegromab in spinal muscular atrophy. Manufacturing and fill-finish facility status remain key watch items.

$ROIVbrepocitinibQ3NDA Dermatomyositis

Priovant / Roivant. NDA Priority Review window for brepocitinib in dermatomyositis. Company has pointed to potential launch timing by end-September if approved.

$QUREAMT-130Q3BLA Huntington’s AA path

uniQure. Planned BLA submission for AMT-130 in Huntington’s disease. Not a PDUFA, but one of the most important regulatory-pathway events in the quarter.

$SLNdivesiranAugData SANRECO Phase 2 PV

Silence Therapeutics. SANRECO Phase 2 topline data for divesiran in polycythemia vera. Important read-through alongside $PTGX / Takeda rusfertide.

$IMMXNXC-201Q3Data AL amyloidosis

Immix Biopharma. NEXICART-2 topline data for NXC-201 in relapsed/refractory AL amyloidosis. BLA-enabling study, high-volatility small-cap setup.

$KPTIselinexorNearData Endometrial cancer Ph3

Karyopharm. XPORT-EC-042 Phase 3 topline data for selinexor in endometrial cancer. Treat as near-term until released or formally delayed.

$KODDAYBREAKQ3Data Wet AMD Phase 3

Kodiak Sciences. DAYBREAK Phase 3 topline data for tarcocimab / KSI-501 in wet AMD. Watch efficacy, durability, dosing interval and safety.

$ALMSenvudeucitinibQ3Data SLE Phase 2b

Alumis. LUMUS Phase 2b readout for envudeucitinib in systemic lupus erythematosus. Autoimmune data can be noisy; dose response matters.

$IVVDVYD2311Q3Data DECLARATION pivotal

Invivyd. DECLARATION pivotal / Phase 3 topline data for VYD2311. COVID-antibody sentiment can be unstable, but pivotal data can still move the name.

$MPLTML-007C-MAMid-AugData ZEPHYR schizophrenia Ph2

MapLight Therapeutics. Phase 2 ZEPHYR topline results for ML-007C-MA in schizophrenia. CNS readout with potentially sharp binary reaction.

$AMLXavexitideQ3Ph3 PBH pivotal LUCIDITY

Amylyx. Phase 3 LUCIDITY topline results for avexitide in post-bariatric hypoglycemia. One of the clearest Phase 3 clinical binaries of the quarter.

$PHVSdeucrictibant ERQ3Ph3 HAE prophylaxis Ph3

Pharvaris. Phase 3 CHAPTER-3 data for extended-release deucrictibant as prophylaxis for hereditary angioedema. Major HAE readout.

$SYRESPY003Q3Data IBD / UC Phase 2

Spyre Therapeutics. Phase 2 SKYLINE Part A topline data for SPY003 in inflammatory bowel disease and ulcerative colitis.

$VERATrutakna / ataciceptQ3eGFR ORIGIN 3 follow-up

Vera Therapeutics. ORIGIN 3 eGFR analysis following accelerated approval. Not another approval decision, but important for durability and confirmatory confidence.

$OCGNOCU410STQ3Data Stargardt interim analysis

Ocugen. Interim OCU410ST analysis after 24 patients complete eight months of follow-up in Stargardt disease. Small-cap ophthalmology catalyst.

$XENEazetukalnerQ3NDA Focal-onset seizures filing

Xenon. Expected NDA submission for azetukalner in focal-onset seizures. Filing confirmation would set up future FDA acceptance and PDUFA timing.

$BBIOinfigratinibQ3NDA Achondroplasia filing

BridgeBio. Expected NDA submission for infigratinib in achondroplasia. Submission timing and acceptance will define the next regulatory leg.

$CLNNCNM-Au8Q3NDA ALS accelerated pathway

Clene. Targeted NDA submission for CNM-Au8 in ALS through an accelerated pathway. Very high regulatory strategy risk because submission does not guarantee acceptance.

$OCGNOCU400Q3BLA Rolling BLA start

Ocugen. Expected start of rolling BLA submission for OCU400 in retinitis pigmentosa. Filing progress, manufacturing and future acceptance are the next watch items.

$MLTXsonelokimabLate SepBLA HS filing watch

MoonLake. Planned BLA submission for sonelokimab in hidradenitis suppurativa around the end of September. Acceptance would create the next formal FDA calendar item.

Most attention-worthy watchlist

$NRXP$REPL$CAPR$RARE$NUVL$IONS$SRRK$AMLX$PHVS$QURE$MPLT

Board rule

Only July–September catalysts are shown. October and later events are intentionally excluded from this compact homepage widget. Resolved decisions are removed from the active board: $CELC Revtorpyk / gedatolisib was approved by the FDA on July 14, ahead of its July 17 PDUFA date, with the U.S. commercial launch expected in Q3 2026; $SNY Sarclisa SC was approved on July 10, ahead of its original July 23 target date. Events with only Q3 guidance are included, but should be rechecked against company filings before trading around them.

Educational content only — not investment advice. Verify dates and filings before trading around binary events. Full catalyst calendar FDA SEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with CONSOB (Italy) and SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.

Avvertenza. Questo contenuto ha finalità esclusivamente didattiche e informative. Non costituisce consulenza finanziaria né una raccomandazione di acquisto o vendita di alcun titolo, in linea con le indicazioni CONSOB (Italia) e SEC (USA). I dati sono generati dall'AI a partire da fonti web e possono contenere errori o non essere aggiornati — verifica sempre rispetto alla fonte primaria collegata. Fai le tue ricerche e consulta un consulente autorizzato. Disclaimer completo: merlintrader.com/disclaimer.